ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000308

Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study

Identifieur interne : 000308 ( PascalFrancis/Corpus ); précédent : 000307; suivant : 000309

Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study

Auteurs : Valerie Voon ; Mandy Sohr ; Anthony E. Lang ; Marc N. Potenza ; Andrew D. Siderowf ; Jacqueline Whetteckey ; Daniel Weintraub ; Glen R. Wunderlich ; Mark Stacy

Source :

Annals of neurology [ 0364-5134 ] ; 2011.

RBID : Pascal:11-0316997

Descripteurs français

Pascal (Inist)
- Trouble du contrôle des impulsions, Maladie de Parkinson, Pathologie du système nerveux, Etude multicentrique, Etude cas témoin.

English descriptors

KwdEn :
- Case control study, Impulse control disorder, Multicenter study, Nervous system diseases, Parkinson disease.

Abstract

Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case-control design. Methods: Patients enrolled in the DOMINION study, a multicenter study assessing the cross-sectional frequency of ICDs in PD, were eligible to participate in the case-control study. PD patients with and without an ICD (n = 282 each) (compulsive gambling, buying, sexual behavior, and eating) were matched individually on age, gender, and dopamine agonist treatment. Subjects were assessed with a comprehensive neurological, psychiatric, and cognitive assessment battery. Results: ICD patients reported more functional impairment (p < 0.001); greater depressive (p < 0.0001), state (p < 0.0001), and trait (p < 0.0001) anxiety; greater obsessive-compulsive symptoms (p < 0.0001); higher novelty-seeking (p < 0.001) and impulsivity (p < 0.001); and differences in reward preference reflecting greater choice impulsivity (p < 0.05). Patients with multiple ICDs had greater dyskinesia scores compared to those with single ICDs. Interpretation: ICDs in PD are associated with multiple psychiatric and cognitive impairments, including affective and anxiety symptoms, as well as elevated obsessionality, novelty seeking, and impulsivity. These results highlight the importance of assessing multiple mental health domains in individuals with PD and ICDs, and suggest possible pathophysiological mechanisms and risk indicators for these disorders.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0364-5134`
A02	`01`			`@0 ANNED3`
A03		`1`		`@0 Ann. neurol.`
A05				`@2 69`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study`
A11	`01`	`1`		`@1 VOON (Valerie)`
A11	`02`	`1`		`@1 SOHR (Mandy)`
A11	`03`	`1`		`@1 LANG (Anthony E.)`
A11	`04`	`1`		`@1 POTENZA (Marc N.)`
A11	`05`	`1`		`@1 SIDEROWF (Andrew D.)`
A11	`06`	`1`		`@1 WHETTECKEY (Jacqueline)`
A11	`07`	`1`		`@1 WEINTRAUB (Daniel)`
A11	`08`	`1`		`@1 WUNDERLICH (Glen R.)`
A11	`09`	`1`		`@1 STACY (Mark)`
A14	`01`			`@1 Behavioral and Clinical Neurosciences Institute, University of Cambridge @2 Cambridge @3 GBR @Z 1 aut.`
A14	`02`			`@1 Boehringer Ingelheim Pharma @2 Ingelheim @3 DEU @Z 2 aut.`
A14	`03`			`@1 University of Toronto @2 Toronto, Ontario @3 CAN @Z 3 aut.`
A14	`04`			`@1 Departments of Psychiatry and Neurobiology and Child Study Center, Yale University School of Medicine @2 New Haven, CT @3 USA @Z 4 aut.`
A14	`05`			`@1 Department of Neurology, University of Pennsylvania School of Medicine @2 Philadelphia, PA @3 USA @Z 5 aut.`
A14	`06`			`@1 Boehringer Ingelheim Pharmaceuticals @2 Ridgefield, CT @3 USA @Z 6 aut.`
A14	`07`			`@1 Department of Psychiatry, University of Pennsylvania School of Medicine @2 Philadelphia, PA @3 USA @Z 7 aut.`
A14	`08`			`@1 Boehringer Ingelheim (Canada) @2 Burlington, Ontario @3 CAN @Z 8 aut.`
A14	`09`			`@1 Department of Neurology, Duke University Medical Center @2 Durham, NC @3 USA @Z 9 aut.`
A20				`@1 986-996`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16555 @5 354000190453440120`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 37 ref.`
A47	`01`	`1`		`@0 11-0316997`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Annals of neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case-control design. Methods: Patients enrolled in the DOMINION study, a multicenter study assessing the cross-sectional frequency of ICDs in PD, were eligible to participate in the case-control study. PD patients with and without an ICD (n = 282 each) (compulsive gambling, buying, sexual behavior, and eating) were matched individually on age, gender, and dopamine agonist treatment. Subjects were assessed with a comprehensive neurological, psychiatric, and cognitive assessment battery. Results: ICD patients reported more functional impairment (p < 0.001); greater depressive (p < 0.0001), state (p < 0.0001), and trait (p < 0.0001) anxiety; greater obsessive-compulsive symptoms (p < 0.0001); higher novelty-seeking (p < 0.001) and impulsivity (p < 0.001); and differences in reward preference reflecting greater choice impulsivity (p < 0.05). Patients with multiple ICDs had greater dyskinesia scores compared to those with single ICDs. Interpretation: ICDs in PD are associated with multiple psychiatric and cognitive impairments, including affective and anxiety symptoms, as well as elevated obsessionality, novelty seeking, and impulsivity. These results highlight the importance of assessing multiple mental health domains in individuals with PD and ICDs, and suggest possible pathophysiological mechanisms and risk indicators for these disorders.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Trouble du contrôle des impulsions @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Impulse control disorder @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Trastorno control impulso @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Etude multicentrique @5 09`
C03	`04`	`X`	`ENG`	`@0 Multicenter study @5 09`
C03	`04`	`X`	`SPA`	`@0 Estudio multicéntrico @5 09`
C03	`05`	`X`	`FRE`	`@0 Etude cas témoin @5 10`
C03	`05`	`X`	`ENG`	`@0 Case control study @5 10`
C03	`05`	`X`	`SPA`	`@0 Estudio caso control @5 10`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 213`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0316997 INIST
ET :	Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study
AU :	VOON (Valerie); SOHR (Mandy); LANG (Anthony E.); POTENZA (Marc N.); SIDEROWF (Andrew D.); WHETTECKEY (Jacqueline); WEINTRAUB (Daniel); WUNDERLICH (Glen R.); STACY (Mark)
AF :	Behavioral and Clinical Neurosciences Institute, University of Cambridge/Cambridge/Royaume-Uni (1 aut.); Boehringer Ingelheim Pharma/Ingelheim/Allemagne (2 aut.); University of Toronto/Toronto, Ontario/Canada (3 aut.); Departments of Psychiatry and Neurobiology and Child Study Center, Yale University School of Medicine/New Haven, CT/Etats-Unis (4 aut.); Department of Neurology, University of Pennsylvania School of Medicine/Philadelphia, PA/Etats-Unis (5 aut.); Boehringer Ingelheim Pharmaceuticals/Ridgefield, CT/Etats-Unis (6 aut.); Department of Psychiatry, University of Pennsylvania School of Medicine/Philadelphia, PA/Etats-Unis (7 aut.); Boehringer Ingelheim (Canada)/Burlington, Ontario/Canada (8 aut.); Department of Neurology, Duke University Medical Center/Durham, NC/Etats-Unis (9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 2011; Vol. 69; No. 6; Pp. 986-996; Bibl. 37 ref.
LA :	Anglais
EA :	Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case-control design. Methods: Patients enrolled in the DOMINION study, a multicenter study assessing the cross-sectional frequency of ICDs in PD, were eligible to participate in the case-control study. PD patients with and without an ICD (n = 282 each) (compulsive gambling, buying, sexual behavior, and eating) were matched individually on age, gender, and dopamine agonist treatment. Subjects were assessed with a comprehensive neurological, psychiatric, and cognitive assessment battery. Results: ICD patients reported more functional impairment (p < 0.001); greater depressive (p < 0.0001), state (p < 0.0001), and trait (p < 0.0001) anxiety; greater obsessive-compulsive symptoms (p < 0.0001); higher novelty-seeking (p < 0.001) and impulsivity (p < 0.001); and differences in reward preference reflecting greater choice impulsivity (p < 0.05). Patients with multiple ICDs had greater dyskinesia scores compared to those with single ICDs. Interpretation: ICDs in PD are associated with multiple psychiatric and cognitive impairments, including affective and anxiety symptoms, as well as elevated obsessionality, novelty seeking, and impulsivity. These results highlight the importance of assessing multiple mental health domains in individuals with PD and ICDs, and suggest possible pathophysiological mechanisms and risk indicators for these disorders.
CC :	002B17; 002B17G
FD :	Trouble du contrôle des impulsions; Maladie de Parkinson; Pathologie du système nerveux; Etude multicentrique; Etude cas témoin
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Impulse control disorder; Parkinson disease; Nervous system diseases; Multicenter study; Case control study
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Trastorno control impulso; Parkinson enfermedad; Sistema nervioso patología; Estudio multicéntrico; Estudio caso control
LO :	INIST-16555.354000190453440120
ID :	11-0316997

Links to Exploration step

Pascal:11-0316997

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study</title>
<author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
<affiliation><inist:fA14 i1="01"><s1>Behavioral and Clinical Neurosciences Institute, University of Cambridge</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name>
<affiliation><inist:fA14 i1="02"><s1>Boehringer Ingelheim Pharma</s1>
<s2>Ingelheim</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="03"><s1>University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
<affiliation><inist:fA14 i1="04"><s1>Departments of Psychiatry and Neurobiology and Child Study Center, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name>
<affiliation><inist:fA14 i1="06"><s1>Boehringer Ingelheim Pharmaceuticals</s1>
<s2>Ridgefield, CT</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name>
<affiliation><inist:fA14 i1="08"><s1>Boehringer Ingelheim (Canada)</s1>
<s2>Burlington, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Neurology, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0316997</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0316997 INIST</idno>
<idno type="RBID">Pascal:11-0316997</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000308</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study</title>
<author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name>
<affiliation><inist:fA14 i1="01"><s1>Behavioral and Clinical Neurosciences Institute, University of Cambridge</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sohr, Mandy" sort="Sohr, Mandy" uniqKey="Sohr M" first="Mandy" last="Sohr">Mandy Sohr</name>
<affiliation><inist:fA14 i1="02"><s1>Boehringer Ingelheim Pharma</s1>
<s2>Ingelheim</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="03"><s1>University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Potenza, Marc N" sort="Potenza, Marc N" uniqKey="Potenza M" first="Marc N." last="Potenza">Marc N. Potenza</name>
<affiliation><inist:fA14 i1="04"><s1>Departments of Psychiatry and Neurobiology and Child Study Center, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D." last="Siderowf">Andrew D. Siderowf</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Whetteckey, Jacqueline" sort="Whetteckey, Jacqueline" uniqKey="Whetteckey J" first="Jacqueline" last="Whetteckey">Jacqueline Whetteckey</name>
<affiliation><inist:fA14 i1="06"><s1>Boehringer Ingelheim Pharmaceuticals</s1>
<s2>Ridgefield, CT</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wunderlich, Glen R" sort="Wunderlich, Glen R" uniqKey="Wunderlich G" first="Glen R." last="Wunderlich">Glen R. Wunderlich</name>
<affiliation><inist:fA14 i1="08"><s1>Boehringer Ingelheim (Canada)</s1>
<s2>Burlington, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Neurology, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Case control study</term>
<term>Impulse control disorder</term>
<term>Multicenter study</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Trouble du contrôle des impulsions</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Etude multicentrique</term>
<term>Etude cas témoin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case-control design. Methods: Patients enrolled in the DOMINION study, a multicenter study assessing the cross-sectional frequency of ICDs in PD, were eligible to participate in the case-control study. PD patients with and without an ICD (n = 282 each) (compulsive gambling, buying, sexual behavior, and eating) were matched individually on age, gender, and dopamine agonist treatment. Subjects were assessed with a comprehensive neurological, psychiatric, and cognitive assessment battery. Results: ICD patients reported more functional impairment (p < 0.001); greater depressive (p < 0.0001), state (p < 0.0001), and trait (p < 0.0001) anxiety; greater obsessive-compulsive symptoms (p < 0.0001); higher novelty-seeking (p < 0.001) and impulsivity (p < 0.001); and differences in reward preference reflecting greater choice impulsivity (p < 0.05). Patients with multiple ICDs had greater dyskinesia scores compared to those with single ICDs. Interpretation: ICDs in PD are associated with multiple psychiatric and cognitive impairments, including affective and anxiety symptoms, as well as elevated obsessionality, novelty seeking, and impulsivity. These results highlight the importance of assessing multiple mental health domains in individuals with PD and ICDs, and suggest possible pathophysiological mechanisms and risk indicators for these disorders.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0>
</fA01>
<fA02 i1="01"><s0>ANNED3</s0>
</fA02>
<fA03 i2="1"><s0>Ann. neurol.</s0>
</fA03>
<fA05><s2>69</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VOON (Valerie)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SOHR (Mandy)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>POTENZA (Marc N.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SIDEROWF (Andrew D.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WHETTECKEY (Jacqueline)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WEINTRAUB (Daniel)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>WUNDERLICH (Glen R.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>STACY (Mark)</s1>
</fA11>
<fA14 i1="01"><s1>Behavioral and Clinical Neurosciences Institute, University of Cambridge</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Boehringer Ingelheim Pharma</s1>
<s2>Ingelheim</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Departments of Psychiatry and Neurobiology and Child Study Center, Yale University School of Medicine</s1>
<s2>New Haven, CT</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Boehringer Ingelheim Pharmaceuticals</s1>
<s2>Ridgefield, CT</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Boehringer Ingelheim (Canada)</s1>
<s2>Burlington, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Neurology, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>986-996</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16555</s2>
<s5>354000190453440120</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>37 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0316997</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case-control design. Methods: Patients enrolled in the DOMINION study, a multicenter study assessing the cross-sectional frequency of ICDs in PD, were eligible to participate in the case-control study. PD patients with and without an ICD (n = 282 each) (compulsive gambling, buying, sexual behavior, and eating) were matched individually on age, gender, and dopamine agonist treatment. Subjects were assessed with a comprehensive neurological, psychiatric, and cognitive assessment battery. Results: ICD patients reported more functional impairment (p < 0.001); greater depressive (p < 0.0001), state (p < 0.0001), and trait (p < 0.0001) anxiety; greater obsessive-compulsive symptoms (p < 0.0001); higher novelty-seeking (p < 0.001) and impulsivity (p < 0.001); and differences in reward preference reflecting greater choice impulsivity (p < 0.05). Patients with multiple ICDs had greater dyskinesia scores compared to those with single ICDs. Interpretation: ICDs in PD are associated with multiple psychiatric and cognitive impairments, including affective and anxiety symptoms, as well as elevated obsessionality, novelty seeking, and impulsivity. These results highlight the importance of assessing multiple mental health domains in individuals with PD and ICDs, and suggest possible pathophysiological mechanisms and risk indicators for these disorders.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Trouble du contrôle des impulsions</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Impulse control disorder</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Trastorno control impulso</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude cas témoin</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Case control study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio caso control</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>213</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0316997 INIST</NO>
<ET>Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study</ET>
<AU>VOON (Valerie); SOHR (Mandy); LANG (Anthony E.); POTENZA (Marc N.); SIDEROWF (Andrew D.); WHETTECKEY (Jacqueline); WEINTRAUB (Daniel); WUNDERLICH (Glen R.); STACY (Mark)</AU>
<AF>Behavioral and Clinical Neurosciences Institute, University of Cambridge/Cambridge/Royaume-Uni (1 aut.); Boehringer Ingelheim Pharma/Ingelheim/Allemagne (2 aut.); University of Toronto/Toronto, Ontario/Canada (3 aut.); Departments of Psychiatry and Neurobiology and Child Study Center, Yale University School of Medicine/New Haven, CT/Etats-Unis (4 aut.); Department of Neurology, University of Pennsylvania School of Medicine/Philadelphia, PA/Etats-Unis (5 aut.); Boehringer Ingelheim Pharmaceuticals/Ridgefield, CT/Etats-Unis (6 aut.); Department of Psychiatry, University of Pennsylvania School of Medicine/Philadelphia, PA/Etats-Unis (7 aut.); Boehringer Ingelheim (Canada)/Burlington, Ontario/Canada (8 aut.); Department of Neurology, Duke University Medical Center/Durham, NC/Etats-Unis (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 2011; Vol. 69; No. 6; Pp. 986-996; Bibl. 37 ref.</SO>
<LA>Anglais</LA>
<EA>Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case-control design. Methods: Patients enrolled in the DOMINION study, a multicenter study assessing the cross-sectional frequency of ICDs in PD, were eligible to participate in the case-control study. PD patients with and without an ICD (n = 282 each) (compulsive gambling, buying, sexual behavior, and eating) were matched individually on age, gender, and dopamine agonist treatment. Subjects were assessed with a comprehensive neurological, psychiatric, and cognitive assessment battery. Results: ICD patients reported more functional impairment (p < 0.001); greater depressive (p < 0.0001), state (p < 0.0001), and trait (p < 0.0001) anxiety; greater obsessive-compulsive symptoms (p < 0.0001); higher novelty-seeking (p < 0.001) and impulsivity (p < 0.001); and differences in reward preference reflecting greater choice impulsivity (p < 0.05). Patients with multiple ICDs had greater dyskinesia scores compared to those with single ICDs. Interpretation: ICDs in PD are associated with multiple psychiatric and cognitive impairments, including affective and anxiety symptoms, as well as elevated obsessionality, novelty seeking, and impulsivity. These results highlight the importance of assessing multiple mental health domains in individuals with PD and ICDs, and suggest possible pathophysiological mechanisms and risk indicators for these disorders.</EA>
<CC>002B17; 002B17G</CC>
<FD>Trouble du contrôle des impulsions; Maladie de Parkinson; Pathologie du   système nerveux; Etude multicentrique; Etude cas témoin</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Impulse control disorder; Parkinson disease; Nervous system diseases; Multicenter study; Case control study</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Trastorno control impulso; Parkinson enfermedad; Sistema nervioso patología; Estudio multicéntrico; Estudio caso control</SD>
<LO>INIST-16555.354000190453440120</LO>
<ID>11-0316997</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000308 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000308 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0316997
   |texte=   Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study

Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri